Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

45th European Brain and Behaviour Society Meeting
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
A gender gap in autoimmunity.
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Gordon Research Conference on Ion Channels
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
NOVANTRONE. mitoXANTRONE for injection concentrate
Studying both sexes: a guiding principle for biomedicine.
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.

Pages